Goldenwell Biotech, INC 10-Q quarterly reports

Goldenwell Biotech, Inc. filed its Q2 2026 10-Q, revealing no revenue, a significant accumulated deficit, and substantial doubt regarding its ability to continue as a going concern, though it did report a minor other income from a legal settlement.

Goldenwell Biotech, Inc. has restated its Q3 2025 financial statements due to accounting errors related to legal fees, service revenue recognition, and prepaid fees.

Goldenwell Biotech, Inc. has issued an amendment to its Q2 2025 Form 10-Q to restate financial statements due to accounting errors.

Goldenwell Biotech, Inc. has issued an amendment to its Q1 2025 Form 10-Q to restate financial results due to an accounting error regarding legal expenses.

Goldenwell Biotech reported a reduced net loss in Q3 2025, driven by new service revenue, but faces significant liquidity challenges and ineffective disclosure controls.

Goldenwell Biotech reported a reduced net loss and increased cash in Q2 2025, but faces significant capital needs and ongoing going concern doubts with zero product sales.

Goldenwell Biotech, Inc. reported continued significant losses and no revenue for Q1 2025, raising substantial doubt about its ability to continue as a going concern, while also disclosing ineffective disclosure controls.

Goldenwell Biotech's Q3 2024 report reveals continued losses and minimal revenue, highlighting the company's reliance on future capital raising for operational sustainability.

Goldenwell Biotech's Q2 2024 results reveal minimal revenue, increased losses, and substantial doubt about the company's ability to continue as a going concern.

Goldenwell Biotech's Q1 2024 results reveal a decrease in revenue and a continued net loss, raising concerns about the company's ability to operate as a going concern.